A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Med Insights Oncol
Autores principales: Oronsky, Bryan, Caroen, Scott, Zeman, Karen, Quinn, Mary, Brzezniak, Christina, Scicinski, Jan, Cabrales, Pedro, Reid, Tony R., Trepel, Jane B., Abrouk, Nacer D., Larson, Christopher, Oronsky, Arnold, Lybeck, Harry E., Day, Regina M., Carter, Corey A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Libertas Academica 2016
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5098407/
https://ncbi.nlm.nih.gov/pubmed/27840583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S40429
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares